tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Buy Rating on Axsome: Strong Commercial Momentum, Expanding CNS Pipeline, and Attractive Valuation Upside
PremiumRatingsBuy Rating on Axsome: Strong Commercial Momentum, Expanding CNS Pipeline, and Attractive Valuation Upside
15h ago
Axsome Therapeutics reports Q4 EPS (56c), consensus (73c)
Premium
The Fly
Axsome Therapeutics reports Q4 EPS (56c), consensus (73c)
16h ago
Axsome Therapeutics sees cash runway into cash flow positivity
Premium
The Fly
Axsome Therapeutics sees cash runway into cash flow positivity
16h ago
Axsome secures long-term SUNOSI exclusivity through Alkem settlement
PremiumCompany AnnouncementsAxsome secures long-term SUNOSI exclusivity through Alkem settlement
7d ago
Axsome Therapeutics settles SUNOSI patent litigation with Alkem
Premium
The Fly
Axsome Therapeutics settles SUNOSI patent litigation with Alkem
7d ago
Axsome Therapeutics price target raised to $195 from $190 at TD Cowen
Premium
The Fly
Axsome Therapeutics price target raised to $195 from $190 at TD Cowen
26d ago
Axsome Therapeutics price target raised to $223 from $148 at Piper Sandler
PremiumThe FlyAxsome Therapeutics price target raised to $223 from $148 at Piper Sandler
1M ago
Axsome Therapeutics initiate FORWARD Phase 3 trial of AXS-14
Premium
The Fly
Axsome Therapeutics initiate FORWARD Phase 3 trial of AXS-14
1M ago
Axsome Therapeutics price target raised to $209 from $157 at Baird
Premium
The Fly
Axsome Therapeutics price target raised to $209 from $157 at Baird
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100